Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Title

Browse by Poster Title

22 results found

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

M
EP-026
MACHINE LEARNING FOR PHARMACOKINETIC/PHARMACODYNAMIC MODELING.

Favorite
PII-035
MACHINE LEARNING-BASED DOSE OPTIMIZATION DESIGN INCORPORATING EXPOSURE-RESPONSE RELATIONSHIP IN CELL THERAPY.

Favorite
PWI-003
MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.

Favorite
PII-112
MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.

Favorite
PT-005
MAJOR POTENTIAL DRUG-DRUG INTERACTIONS AMONG MEDICAID-INSURED CHILDREN IN THE OUTPATIENT SETTING.

Favorite
PII-036
MASS BALANCE AND METABOLITE IDENTIFICATION OF VALEMETOSTAT AFTER A SINGLE ORAL ADMINISTRATION IN HEALTHY MALE SUBJECTS.

Favorite
PT-001
MAXIMUM LIKELIHOOD ESTIMATION OF RENAL TRANSPORTER ONTOGENY PROFILES FOR PEDIATRIC PBPK MODELING.

Favorite
EP-035
MECHANISTIC POPULATION PHARMACOKINETIC MODELLING OF RISDIPLAM FOR EXTRAPOLATION OF EXPOSURE AND CYP3A DRUG-DRUG INTERACTION IN NEONATES WITH SPINAL MUSCULAR ATROPHY.

Favorite
EP-011
METABOLIC PROFILE INVESTIGATION REVEALS WIDE VARIABILITY IN THE EXPOSURE OF ISONIAZID AND ITS HEPATOTOXIC METABOLITES IN TUBERCULOSIS PATIENTS.

Favorite
PII-060
METHOTREXATE POPULATION PHARMACOKINETICS IN PATIENTS WITH PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY.

Favorite
PII-049
MIRNA-125A ASSOCIATION WITH CARFILZOMIB-RELATED CARDIOVASCULAR ADVERSE EVENTS IN MULTIPLE MYELOMA PATIENTS: PROSPECTIVE OBSERVATION OF CARDIAC SAFETY WITH PROTEASOME INHIBITOR (PROTECT) STUDY.

Favorite
PII-061
MODEL INFORMED DRUG DEVELOPMENT (MIDD) TO SUPPORT AN ALTERNATIVE NIVOLUMAB DOSE AND SCHEDULE FOR ADVANCED MELANOMA.

Favorite
PII-096
MODEL INFORMED DRUG INTERACTION STUDY DESIGN FOR VESATOLIMOD AND CYP3A/P-GP MODULATORS USING PBPK.

Favorite
PII-062
MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.

Favorite
PWII-001
MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.

Favorite
EP-017
MODEL-INFORMED VANCOMYCIN DOSING TO ADDRESS DELAYED RENAL MATURATION IN INFANTS AND YOUNG CHILDREN WITH CONGENITAL HEART DISEASE.

Favorite
PII-063
MODELING AND SIMULATION TO SUPPORT APIXABAN DOSE RECOMMENDATION FOR THROMBOEMBOLISM PREVENTION IN PEDIATRIC SUBJECTS WITH CONGENITAL OR ACQUIRED HEART DISEASE REQUIRING ANTICOAGULATION – SAXOPHONE STUDY.

Favorite
PII-064
MODELING MORTALITY OF PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION USING SUPERVISED MACHINE LEARNING.

Favorite
LB-004
MOLNUPIRAVIR EXPOSURE-RESPONSE OF CLINICAL OUTCOMES IN TREATMENT OF COVID-19.

Favorite
LB-005
MOLNUPIRAVIR EXPOSURE-RESPONSE RELATIONSHIPS FOR CLINICAL OUTCOMES, VIROLOGY, AND MECHANISM OF ACTION BIOMARKERS ARE CONSISTENT IN TREATMENT OF COVID-19.

Favorite
PII-037
MTD IN DRUG COMBO: AN EXPERT CURATED MTD DATA SET FOR EFFICIENT DRUG COMBINATION PHASE 1 TRIAL DESIGN.

Favorite
PII-038
MULTICENTER PHARMACOKINETIC STUDY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER IN OLDER ADULTS AGED OVER 75 YEARS.

Favorite